At Zai, we are committed to building a highly collaborative team that shares common goals. Dr. Rafael Amado, President and Head of Global R&D, speaks with Life Science Success Podcast about why he joined Zai Lab and how our ongoing #collaboration fosters growth worldwide. Learn more about Zai’s global footprint: https://bit.ly/3vvYvCg #innovation #healthcare #pharmaceuticals #biotech
关于我们
再鼎医药是一家立足中国、全球运营的创新型生物制药公司，致力于为中国及全球的患者提供癌症、自体免疫及感染性疾病领域的创新药物。 再鼎医药总部位于上海，自2014年成立以来，已与多个全球领先的生物制药公司建立了合作伙伴关系，打造起广泛的后期创新候选药物产品线。对于寻求进入中国市场以及寻找国际临床开发长期战略合作伙伴的全球生物制药公司来说，再鼎医药凭借一系列成功合作案例，成为了业界最值得信赖的合作伙伴人选之一。通过这些成功合作，再鼎医药打造起中国创新生物技术公司中最强大的晚期肿瘤产品管线，拥有多个全球同类首个和/或同类最佳药物。同时我们正在不断提高内部研发能力，以进一步补充我们的产品线，目标是未来每年可以有1-2个全球新药临床试验申请（IND）。 再鼎医药正在快速发展成为一家全面整合的生物制药公司，在中国和全球各地发现、开发、生产并商业化创新药物。为此，我们在中国成立了内部研发中心以推动药物研发，打造了一支强大的临床开发和运营团队，并建立了自有的生产基地。此外，我们还成立了一支专业化的商业团队，以支持创新产品在中国的推广。我们相信，这种整合策略将为再鼎医药带来可持续的竞争优势。 再鼎医药于2017年9月在美国纳斯达克成功上市。此后，公司快速发展，已在中国多地设立分公司或办事处，并于2018年12月在美国旧金山成立美国总部。截至2019年12月，公司在全球共拥有大约700名员工。
- 网站
-
http://www.zailaboratory.com
再鼎医药的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Zhangjiang Hi-tech Park, Pudong，Shanghai
- 类型
- 上市公司
- 创立
- 2014
地点
再鼎医药员工
动态
-
Zai Lab is pleased to announce, along with our partner argenx, the approval of the first and only subcutaneous injectable treatment option for patients with generalized myasthenia gravis (gMG) in China. This approval marks a key advancement in the accessibility and flexibility of care for patients with #gMG in China. Read the full release here: https://bit.ly/466CvvL #innovation #healthcare
-
-
Zai Lab is proud to support the first publication in Cell from China's #gynecology #oncology field. This study provides new insights with the potential to improve treatment options for homologous recombination deficiency (HRD) positive ovarian cancers. To learn more, visit: https://bit.ly/3y5BW8U #innovation #healthcare
-
-
At Zai Lab, we're driven by #innovation. Over the last 10 years, we've been working toward improving outcomes for patients with serious illnesses in key areas such as #oncology and #immunology. Hear more from Rafael Amado President & Head of Global R&D, in his interview with Life Science Success Podcast: [https://bit.ly/3Lbz1hV] #healthcare
-
Congratulations to our partner argenx on their #FDA approval for a new treatment option for patients with chronic inflammatory demyelinating polyneuropathy. China's NMPA is currently reviewing Zai Lab's sBLA with priority review for this treatment. #CIDP #innovation
Today we announced the FDA approval of a new treatment for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). This approval marks a key advancement in the understanding of rare, autoimmune diseases, and we are proud to deliver a new, innovative option for the #CIDP community. #TogetherWeDiscover Learn more: https://bit.ly/45D76Rl
-
Congratulations to our partner Bristol Myers Squibb on their #FDA approval of a next-generation therapy option for patients with NTRK+ solid tumors. Zai Lab is proud to collaborate with BMS to bring new therapies to patients. #oncology #innovation
-
#NEWS: Today we launched our first global Ph2 trial, which will evaluate a potential new treatment for individuals with chronic plaque #psoriasis. This #milestone highlights Zai's growing global capabilities and pipeline of innovative, internally developed investigational therapies. Read the full press release here: https://bit.ly/4buwoDB #autoimmunity #innovation
-
#NEWS: We’ve received approval in China for a new drug to treat hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii. The World Health Organization considers Acinetobacter a top-priority pathogen worldwide that needs novel antibiotics. Read more about our #milestone that could help address an urgent global health need: https://bit.ly/4bn07OA #approval #drugresistantinfection #infectiousdiseases #innovation
Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in China – Zai...
ir.zailaboratory.com
-
From our partner Innoviva Specialty Therapeutics, Inc.
Matthew Ronsheim, PhD, President of Innoviva Specialty Therapeutics, is excited to announce that the National Medical Products Administration (NMPA) of China has approved XACDURO for the treatment of hospital-acquired and ventilator-associated pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex in patients 18 years of age and older. Read more details here: https://lnkd.in/e8dRvvTs
-